Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia

NCT00074074 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT00074074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00074074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
Not reported
Enrollment
46 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes